Starpharma Holdings Ltd banner

Starpharma Holdings Ltd
ASX:SPL

Watchlist Manager
Starpharma Holdings Ltd Logo
Starpharma Holdings Ltd
ASX:SPL
Watchlist
Price: 0.5 AUD 2.04%
Market Cap: AU$210m

Starpharma Holdings Ltd
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Starpharma Holdings Ltd
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Starpharma Holdings Ltd
ASX:SPL
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Other
AU$1.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Other
AU$3.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Other
-AU$15k
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Other
-AU$193.4k
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nyrada Inc
ASX:NYR
Other
-AU$254k
CAGR 3-Years
2%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

Starpharma Holdings Ltd
Glance View

Market Cap
210m AUD
Industry
Pharmaceuticals

Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.

SPL Intrinsic Value
Not Available

See Also

Back to Top